CYP2C19 assay and screening systems, P450-Glo™

Supplier: Promega

Certificates

Supplier: Promega

About this item

The P450-Glo CYP2C19 assays provide a homogeneous, luminescent method for measuring cytochrome CYP2C19 activity.

Broad dynamic range, low background and better sensitivity for less ambiguous data
Luminescent output eliminates interference from fluorescent test compounds
Optimal data quality for microplate reader assay
Simplified, homogeneous experimental protocol

The P450-Glo CYP2C19 screening system provides a complete set of reagents for performing luminescent cytochrome P450 assays. The membranes are prepared from baculovirus-infected insect cells and contain human cytochrome P450, P450 reductase, and cytochrome b5. It also contains a membrane fraction devoid of cytochrome P450 activity as a negative control. The assays are ideal for testing the effects of drugs and new chemical entities on cytochrome P450 enzyme activities.

Delivery: Assay system contains Luciferin-H EGE (1×123 or 2×123 µg); luciferin detection reagent (lyophilised) (1 vial); reconstitution buffer with esterase (1×10 or 1×50 ml). Screening system contains P-Glo CYP2C19 assay includes Luciferin-H EGE (2×123 µg); luciferin detection reagent (lyophilised) (1 vial); reconstitution buffer with esterase (50 ml) and human CYP2C19 enzyme system includes CYP2C19 (1 pmol/µl), reductase and b5 (250 µl); control membranes (100 µl); potassium phosphate buffer, 1M (pH 7.4) (5 ml); luciferin-free water (50 ml); NADPH regeneration system solution A (2,75 ml); NADPH regeneration system solution B (0,6 ml).